Alert detail

LCD L39686: MolDX: Gene Expression Profile Tests for Decision-Making in Castration Resistant and Metastatic Prostate Cancers — Noridian

Policy ID: LCD-L39686Specialty: OncologyAdded: 6/5/2026Effective: January 22, 2026lcd
Routine

What changed

Key updates for prostate cancer decision-making tests.

Who’s affected: Oncology billing teams · Effective: January 22, 2026

Affected codes

Primary source: View the official CMS/MAC document ↗

Get the action steps and full analysis

This change affects 7 billing codes.

Subscribers get the recommended action (“what to do”), the full AI analysis, the LCD revision comparison, and related alerts across your specialty and jurisdiction.

Audit documentation

Building an audit file?

The Tripwire Audit Pack exports 12 months of Oncology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.

Get the Oncology audit pack — $349One-time purchase · not a subscription

Not ready to subscribe?

Get the free weekly reimbursement brief for Oncology— the week’s changes and deadlines, delivered to your inbox. No account required.